MDM shares its findings in journals and at professional conferences.



Publications

MDM has published in a variety of scientific journals. MDM’s publications are primarily model-focused and address a wide range of medical conditions. Furthermore, MDM personnel are frequent reviewers of manuscripts for the journals Medical Decision Making and Value in Health.

Bold type denotes MDM employee at time of research contribution.

  • Smolen HJ, Murphy DR, Gahn JC, Yu X, Curtis BH. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus. J Manag Care Pharm 2014;20(9):968-984.

  • Smolen LJ, Klein TM, Bly CA, Ryan KJ. Cost-effectiveness of live attenuated versus inactivated influenza vaccine among children. The American Journal of Pharmacy Benefits 2014;6(4):171-182.

  • Li Y, Zhu M, Klein R, Kong N. Using a partially observable Markov chain model to assess colonoscopy screening strategies-- A cohort study. European Journal of Operational Research 2014;238(1):313-326.

  • Myers J, Wielage RC, Han B, Price K, Gahn J, Paget MA, Happich M. The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis. BMC Musculoskeletal Disorders 2014;15(1):76.

  • Furiak N, Duhig AM, Myers J, Pitts A, Hass S, Klein R. Economic considerations of cognition and functional outcomes in patients with schizophrenia: a systematic literature review. Schizophrenia Research: Cognition 2014;1(1):e27-e33.

  • Wielage RC, Patel A, Bansal M, Lee S, Klein R, Happich M. The cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective. Arthritis Care and Research 2014;66(5):702-8.

  • Wielage RC, Myers JA, Klein RW, Happich M. Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review. Applied Health Economics and Health Policy 2013. Dec;11(6):593-618.

  • Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective. Applied Health Economics and Health Policy 2013 Jun;11(3):219-36.

  • Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein R, Happich M. The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective. Value in Health 2013 Mar-Apr;16(2):334-44.

  • Wielage R, Bansal M, Wilson K, Klein R, Happich M. The cost-effectiveness of duloxetine in chronic low back pain; a Quebec societal perspective. Spine 2013 May 15;38(11):936-46.

  • Murphy DR, Klein RW, Smolen LJ, Klein TM, Roberts SD. Using common random numbers in healthcare cost-effectiveness simulation modeling. Health Services Research 2013; 48(4):1508-25.

  • Lee LJ, Smolen LJ, Klein TM, Foster SA, Whiteman D, Jorgenson JA, Hultgren S. Budget impact analysis of insulin therapies and associated delivery systems. Am J Health Syst Pharm 2012; 69(11):958-65.

  • Gandhi SK, Jensen MM, Fox KM, Smolen L, Olsson AG, Paulson. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. Clinicoecon Outcomes Res 2012; 4:1-11. http://www.dovepress.com/cost-effectiveness-of-rosuvastatin-in-comparison-with-generic-atorvast-peer-reviewed-article-CEOR

  • Furiak NM, Gahn JC, Klein RW, Camper SB, Summers KH. Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model. Ann Gen Psychiatry 2012;11(1):29. http://www.annals-general-psychiatry.com/content/11/1/29

  • Murphy DR, Smolen LJ, Klein TM, Klein RW. The cost effectiveness of teriparatide as a first line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskeletal Disorders 2012;13:213. http://www.biomedcentral.com/1471-2474/13/213

  • Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, Culler SD. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. Journal of Medical Economics 2012;15(3):531-47.

  • Furiak NM, Kahle-Wrobleski K, Callahan C, Klein TM, Klein RW, Siemers ER. Screening and treatment for Alzheimer's disease: Predicting population-level outcomes. Alzheimer's & Dementia 2012;8:31-38.

  • Kessler WR, Imperiale TF, Klein RW, Wielage RC, Rex DK. A quantitative assessment of the risks and cost savings of forgoing histologic examination of diminutive polyps. Endoscopy 2011;43:683-91. [Epub May 27 2011].

  • Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, Conley RR. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Current Med Res & Opin. 2011;27(4):713-30.

  • Yaesoubi R, Roberts SD, Klein RW. A modification of Cheng's method: an alternative factor screening method for stochastic simulation models. 2010 Winter Simulation Conference Proceedings, IEEE, Piscataway, NJ. 2010:1034-47.

  • Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010 Sep;13(3):428-37.

  • Klein R, Wielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, Schwartzberg L. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010 Aug;5(8):1263-72.

  • Furiak NM, Klein RW, Kahle-Wrobleski K, Siemers ER, Sarpong E, Klein TM. Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model. BMC Med Inform Decis Mak. 2010 Apr 30;10:24.

  • Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R, Schwartzberg L. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2009 Nov;4(11):1404-14.

  • Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value in Health 2010;13:77-86. First published online 24 Aug 2009.

  • Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, Culler SD. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009 Apr 7;7:4.

  • Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: a meta-analysis and decision analysis. Obstetrics & Gynecology 2009;113(3):585-94.

  • Tafazzoli A, Roberts S, Ness R, Klein R, Dittus R. Probabilistic cost-effectiveness comparison of screening strategies for colorectal cancer. ACM Transactions on Modeling and Computer Simulation 2009;19(2):1-29.

  • Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009 Jan 12;2:6.

  • Roberts S, Wang L, Klein R, Ness R, Dittus R. Development of a simulation model of colorectal cancer. ACM Transactions on Modeling and Computer Simulation 2008;18(1):1-30.

  • Smolen HJ, Cohen DJ, Samsa GP, Toole JF, Klein RW, Furiak NM, Lorell BH. Development, validation, and application of a microsimulation model to predict stroke and mortality in medically-managed asymptomatic patients with significant carotid artery stenosis. Value Health. 2007;10(6):489-97.

  • Imperiale TF, Klein RW, Chalasani N. A Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. Hepatology 2007;45(4):870-8.

  • Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Women's Health 2007;7:6. http://www.biomedcentral.com/content/pdf/1472-6874-7-6.pdf

  • Ness RM, Klein RW, Dittus RS. Appendix G The Vanderbilt Colorectal Cancer Model. In Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Pignone M, Russell L, Wagner J, eds. Washington DC, National Academies Press 2005. Available at:
    http://www.iom.edu/CMS/3798/15652/25197.aspx.

  • Ohsfeldt RL, Kreder KJ, Klein RW, Chrischilles EA. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. J Manag Care Pharm. 2004;10(5):412-22.

  • Imperiale TF, Chalasani N, Klein RW. Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis. Am J Gastroenterol. 2003;98(12):2742-50.

  • Ness RM, Holmes A, Klein R, Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol. 2000;95(7):1800-11.

  • Ness RM, Holmes A, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999,94(7):1650-7.